Gleneagles Hospital Hong Kong’s Peritoneal Malignancy Treatment Centre has introduced new intraperitoneal chemotherapy procedures, including Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC), to provide more effective treatment to patients with peritoneal cancer.
Dr Kenneth Tsang, Chief Executive Officer of Gleneagles Hospital Hong Kong, said, “In addition to our advanced radiotherapy facilities, we have also launched a centre dedicated to serving patients with peritoneal metastasis. Our experienced multidisciplinary medical team provides patients with comprehensive diagnostic services and personalised treatments.” The Centre is the first of its kind in Hong Kong catering to patients with peritoneal metastasis. Medical studies have found HIPEC to effectively improve the survival rate of patients with ovarian cancer, gastric cancer or colorectal cancer. The innovative PIPAC treatment is also known to relieve symptoms of peritoneal metastasis and reduce the side effects of chemotherapy, which helps improve the patient’s quality of life.
Related Stories
Rise Above the Waves: IHH Banner Flies High at International Dragon Boat Championship
IHH Malaysia Empowers Allied Health Professionals at National Conference
Fortis Healthcare Expands Footprint with New 200-Bed Hospital in Greater Noida
See how Fortis strengthens its Delhi-NCR network and enhances access to quality care.
Fortis Manesar Breaks New Ground in Cardiac Care
Discover how a life-changing, minimally invasive procedure gave a 16-year-old patient a second chance
IHH Healthcare Debuts FutureHealth.Now Conference
See how we united visionary minds across healthcare, government and business to spark bold ideas and forge new partnerships that will push the boundaries of care at our inaugural global leadership conference.
